Latest Breaking News On - Refractory status - Page 1 : vimarsana.com

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting News provided by Share this article Share this article NEWTON, Mass., May 19, 2021 /PRNewswire/  Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that sixteen abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 4-8, 2021. Key abstracts to be presented at the meeting will feature clinical data for XPOVIO® (selinexor), the Company s first in class, oral Selective Inhibitor of Nuclear Export (SINE) compound, including: (i) multiple new subgroup analyses from the pivotal Phase 3 BOSTON study, including data results evaluating XPOVIO treatment for patients over the age of 65 years old and patients with RAS-mutated multiple myeloma; (ii

United statesUniversity hospitalXavier leleuChristopherj walkerMike dolphTalia golanShannon westinSangmin leeYasaman demastaniCesar serranoDarrell whiteCristina gasparettoThierry faconYazmin odiaSharon shachamSelective inhibitor of nuclear export